|
1
|
Hunger SP and Mullighan CG: Acute
lymphoblastic leukemia in children. N Engl J Med. 373:1541–1552.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Anderson K, Lutz C, van Delft FW, Bateman
CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J,
et al: Genetic variegation of clonal architecture and propagating
cells in leukaemia. Nature. 469:356–361. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Moorman AV: New and emerging prognostic
and predictive genetic biomarkers in B-cell precursor acute
lymphoblastic leukemia. Haematologica. 101:407–416. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zadka L, Kulus MJ and Piatek K: ADAM
protein family-its role in tumorigenesis, mechanisms of
chemoresistance and potential as diagnostic and prognostic factors.
Neoplasma. 65:823–839. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dong F, Eibach M, Bartsch JW, Dolga AM,
Schlomann U, Conrad C, Schieber S, Schilling O, Biniossek ML,
Culmsee C, et al: The metalloprotease-disintegrin ADAM8 contributes
to temozolomide chemoresistance and enhanced invasiveness of human
glioblastoma cells. Neuro Oncol. 17:1474–1485. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mullooly M, McGowan PM, Kennedy SA, Madden
SF, Crown J, O' Donovan N and Duffy MJ: ADAM10: A new player in
breast cancer progression? Br J Cancer. 113:945–951.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Richards FM, Tape CJ, Jodrell DI and
Murphy G: Anti-tumor effects of a specific anti-ADAM17 antibody in
an ovarian cancer model in vivo. PLoS One. 7(e40597)2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bolger JC and Young LS: ADAM22 as a
prognostic and therapeutic drug target in the treatment of
endocrine-resistant breast cancer. Vitam Horm. 93:307–321.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Saftig P and Reiss K: The ‘a disintegrin
and metalloproteases’ ADAM10 and ADAM17: Novel drug targets with
therapeutic potential? Eur J Cell Biol. 90:527–535. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Smith M, Arthur D, Camitta B, Carroll AJ,
Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, et al:
Uniform approach to risk classification and treatment assignment
for children with acute lymphoblastic leukemia. J Clin Oncol.
14:18–24. 1996.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Schwarz J, Schmidt S, Will O, Koudelka T,
Köhler K, Boss M, Rabe B, Tholey A, Scheller J, Schmidt-Arras D, et
al: Polo-like kinase 2, a novel ADAM17 signaling component,
regulates tumor necrosis factor α ectodomain shedding. J Biol Chem.
289:3080–3093. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gessi M, Japp AS, Dreschmann V, Zur Mühlen
A, Goschzik T, Dörner E and Pietsch T: High-resolution genomic
analysis of cribriform neuroepithelial tumors of the central
nervous system. J Neuropathol Exp Neurol. 74:970–974.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
You B, Gu M, Cao X, Li X, Shi S, Shan Y
and You Y: Clinical significance of ADAM10 expression in laryngeal
carcinoma. Oncol Lett. 13:1353–1359. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Barrow J, Adamowicz-Brice M, Cartmill M,
MacArthur D, Lowe J, Robson K, Brundler MA, Walker DA, Coyle B and
Grundy R: Homozygous loss of ADAM3A revealed by genome-wide
analysis of pediatric high-grade glioma and diffuse intrinsic
pontine gliomas. Neuro Oncol. 13:212–222. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu Z, Piao L, Zhuang M, Qiu X, Xu X,
Zhang D, Liu M and Ren D: Silencing of histone methyltransferase
NSD3 reduces cell viability in osteosarcoma with induction of
apoptosis. Oncol Rep. 38:2796–2802. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Asnaghi L, Alkatan H, Mahale A, Othman M,
Alwadani S, Al-Hussain H, Jastaneiah S, Yu W, Maktabi A, Edward DP
and Eberhart CG: Identification of multiple DNA copy number
alterations including frequent 8p11.22 amplification in
conjunctival squamous cell carcinoma. Invest Ophthalmol Vis Sci.
55:8604–8613. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Flossbach L, Holzmann K, Mattfeldt T, Buck
M, Lanz K, Held M, Möller P and Barth TF: High-resolution genomic
profiling reveals clonal evolution and competition in
gastrointestinal marginal zone B-cell lymphoma and its large cell
variant. Int J Cancer. 132:E116–E127. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Saloura V, Vougiouklakis T, Zewde M,
Kiyotani K, Park JH, Gao G, Karrison T, Lingen M, Nakamura Y and
Hamamoto R: WHSC1L1 drives cell cycle progression through
transcriptional regulation of CDC6 and CDK2 in squamous cell
carcinoma of the head and neck. Oncotarget. 7:42527–42538.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sun L, Li M, Huang X, Xu J, Gao Z and Liu
C: High-resolution genome-wide analysis identified recurrent
genetic alterations in NK/T-cell lymphoma, nasal type, which are
associated with disease progression. Med Oncol.
31(71)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dun KA, Vanhaeften R, Batt TJ, Riley LA,
Diano G and Williamson J: BCR-ABL1 gene rearrangement as a
subclonal change in ETV6-RUNX1-positive B-cell acute
lymphoblastic leukemia. Blood Adv. 1:132–138. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cai Y, Crowther J, Pastor T, Abbasi Asbagh
L, Baietti MF, De Troyer M, Vazquez I, Talebi A, Renzi F, Dehairs
J, et al: Loss of chromosome 8p governs tumor progression and drug
response by altering lipid metabolism. Cancer Cell. 29:751–766.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kluth M, Amschler NN, Galal R, Möller-Koop
C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C,
Steurer S, et al: Deletion of 8p is an independent prognostic
parameter in prostate cancer. Oncotarget. 8:379–392.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lebok P, Mittenzwei A, Kluth M, Özden C,
Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, et
al: 8p deletion is strongly linked to poor prognosis in breast
cancer. Cancer Biol Ther. 16:1080–1087. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Moelans CB, van Maldegem CMG, van der Wall
E and van Diest PJ: Copy number changes at 8p11-12 predict adverse
clinical outcome and chemo- and radiotherapy response in breast
cancer. Oncotarget. 9:17078–17092. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kadekar S, Peddada S, Silins I, French JE,
Högberg J and Stenius U: Gender differences in chemical
carcinogenesis in national toxicology program 2-year bioassays.
Toxicol Pathol. 40:1160–1168. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bonilla MA and Menell JS: Disorders of
white blood cells. In: Lanzkowsky's manual of pediatric hematology
and oncology. 6th edition. Lanzkowsky P, Lipton JL and Fish JD
(eds). Academic Press. pp209–238. 2016.
|
|
27
|
Krawczyk J, O'Dwyer M, Swords R, Freeman C
and Giles FJ: The role of inflammation in leukaemia. In:
Inflammation and cancer. Advances in Experimental Medicine and
Biology. Vol 816:Springer, Basel. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Aggarwal BB and Gehlot P: Inflammation and
cancer: How friendly is the relationship for cancer patients? Curr
Opin Pharmacol. 9:351–369. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dubey S, Vanveldhuizen P, Holzbeierlein J,
Tawfik O, Thrasher JB and Karan D: Inflammation-associated
regulation of the macrophage inhibitory cytokine (MIC-1) gene in
prostate cancer. Oncol Lett. 3:1166–1170. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Matsuno O, Miyazaki E, Nureki S, Ueno T,
Ando M, Ito K, Kumamoto T and Higuchi Y: Elevated soluble ADAM8 in
bronchoalveolar lavage fluid in patients with eosinophilic
pneumonia. Int Arch Allergy Immunol. 142:285–290. 2007.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bridges LC, Sheppard D and Bowditch RD:
ADAM disintegrin-like domain recognition by the lymphocyte
integrins alpha4beta1 and alpha4beta7. Biochem J. 387:101–108.
2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Namba K, Nishio M, Mori K, Miyamoto N,
Tsurudome M, Ito M, Kawano M, Uchida A and Ito Y: Involvement of
ADAM9 in multinucleated giant cell formation of blood monocytes.
Cell Immunol. 213:104–113. 2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Richens J, Fairclough L, Ghaemmaghami AM,
Mahdavi J, Shakib F and Sewell HF: The detection of ADAM8 protein
on cells of the human immune system and the demonstration of its
expression on peripheral blood B cells, dendritic cells and
monocyte subsets. Immunobiology. 212:29–38. 2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Seabra AD, Araújo TM, Mello Junior FA, Di
Felipe Ávila Alcântara D, De Barros AP, De Assumpção PP, Montenegro
RC, Guimarães AC, Demachki S, Burbano RM and Khayat AS:
High-density array comparative genomic hybridization detects novel
copy number alterations in gastric adenocarcinoma. Anticancer Res.
34:6405–6415. 2014.PubMed/NCBI
|
|
35
|
Chiu CG, Nakamura Y, Chong KK, Huang SK,
Kawas NP, Triche T, Elashoff D, Kiyohara E, Irie RF, Morton DL and
Hoon DS: Genome-wide characterization of circulating tumor cells
identifies novel prognostic genomic alterations in systemic
melanoma metastasis. Clin Chem. 60:873–885. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li L, Peng M, Xue W, Fan Z, Wang T, Lian
J, Zhai Y, Lian W, Qin D and Zhao J: Integrated analysis of
dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of
lung adenocarcinoma. J Transl Med. 16(372)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Colaprico A, Olsen C, Bailey MH, Odom GJ,
Terkelsen T, Silva TC, Olsen AV, Cantini L, Zinovyev A, Barillot E,
et al: Interpreting pathways to discover cancer driver genes with
moonlight. Nat Commun. 11(69)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ma S, Xu J, Wang X, Wu QY, Cao J, Li ZY,
Zeng LY, Chen C and Xu KL: Effect of ADAM10 inhibitor GI254023X on
proliferation and apoptosis of acute T-lymphoblastic leukemia
jurkat cells in vitro and its possible mechanisms. Zhongguo Shi Yan
Xue Ye Xue Za Zhi. 23:950–955. 2015.(In Chinese). PubMed/NCBI View Article : Google Scholar
|
|
39
|
Mullooly M, McGowan PM, Crown J and Duffy
MJ: The ADAMs family of proteases as targets for the treatment of
cancer. Cancer Biol Ther. 17:870–880. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Fu L, Liu N, Han Y, Xie C, Li Q and Wang
E: ADAM10 regulates proliferation, invasion, and chemoresistance of
bladder cancer cells. Tumour Biol. 35:9263–9268. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Liu WH and Chang LS: Suppression of
ADAM17-mediated Lyn/Akt pathways induces apoptosis of human
leukemia U937 cells: Bungarus multicinctus protease inhibitor-like
protein-1 uncovers the cytotoxic mechanism. J Biol Chem.
285:30506–30515. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Blanchot-Jossic F, Jarry A, Masson D,
Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL and Mosnier JF:
Up-regulated expression of ADAM17 in human colon carcinoma:
Co-expression with EGFR in neoplastic and endothelial cells. J
Pathol. 207:156–163. 2005.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tanaka Y, Miyamoto S, Suzuki SO, Oki E,
Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E and
Nakano H: Clinical significance of heparin-binding epidermal growth
factor-like growth factor and a disintegrin and metalloprotease 17
expression in human ovarian cancer. Clin Cancer Res. 11:4783–4792.
2005.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ringel J, Jesnowski R, Moniaux N, Lüttges
J, Ringel J, Choudhury A, Batra SK, Klöppel G and Löhr M: Aberrant
expression of a disintegrin and metalloproteinase 17/tumor necrosis
factor-alpha converting enzyme increases the malignant potential in
human pancreatic ductal adenocarcinoma. Cancer Res. 66:9045–9053.
2006.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Takamune Y, Ikebe T, Nagano O and
Shinohara M: Involvement of NF-kappaB-mediated maturation of
ADAM-17 in the invasion of oral squamous cell carcinoma. Biochem
Biophys Res Commun. 365:393–398. 2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Fourie AM, Coles F, Moreno V and Karlsson
L: Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on
synthetic peptide substrates and in ectodomain cleavage of CD23. J
Biol Chem. 278:30469–30477. 2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Mitsui Y, Mochizuki S, Kodama T, Shimoda
M, Ohtsuka T, Shiomi T, Chijiiwa M, Ikeda T, Kitajima M and Okada
Y: ADAM28 is overexpressed in human breast carcinomas: Implications
for carcinoma cell proliferation through cleavage of insulin-like
growth factor binding protein-3. Cancer Res. 66:9913–9920.
2006.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ohtsuka T, Shiomi T, Shimoda M, Kodama T,
Amour A, Murphy G, Ohuchi E, Kobayashi K and Okada Y: ADAM28 is
overexpressed in human non-small cell lung carcinomas and
correlates with cell proliferation and lymph node metastasis. Int J
Cancer. 118:263–273. 2006.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zhang XH, Wang CC, Jiang Q, Yang SM, Jiang
H, Lu J, Wang QM, Feng FE, Zhu XL, Zhao T and Huang XJ: ADAM28
overexpression regulated via the PI3K/Akt pathway is associated
with relapse in de novo adult B.cell acute lymphoblastic leukemia.
Leuk Res, 2015 (Epub ahead of print).
|
|
50
|
Twito T, Chen Z, Khatri I, Wong K, Spaner
D and Gorczynski R: Ectodomain shedding of CD200 from the B-CLL
cell surface is regulated by ADAM28 expression. Leuk Res.
37:816–821. 2013.PubMed/NCBI View Article : Google Scholar
|
